[go: up one dir, main page]

NO20075400L - Fremgangsmater, sammensetninger og formuleringer for a forebygge eller lindre ugunstige virkninger i en pasient - Google Patents

Fremgangsmater, sammensetninger og formuleringer for a forebygge eller lindre ugunstige virkninger i en pasient

Info

Publication number
NO20075400L
NO20075400L NO20075400A NO20075400A NO20075400L NO 20075400 L NO20075400 L NO 20075400L NO 20075400 A NO20075400 A NO 20075400A NO 20075400 A NO20075400 A NO 20075400A NO 20075400 L NO20075400 L NO 20075400L
Authority
NO
Norway
Prior art keywords
patient
formulations
compositions
methods
preventing
Prior art date
Application number
NO20075400A
Other languages
English (en)
Other versions
NO342207B1 (no
Inventor
Dennis Mangano
Original Assignee
Pericor Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pericor Therapeutics Inc filed Critical Pericor Therapeutics Inc
Publication of NO20075400L publication Critical patent/NO20075400L/no
Publication of NO342207B1 publication Critical patent/NO342207B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Det beskrives metoder, preparater, formuleringer og sett i forbindelse med akadesin, et prodrug, en analog eller et salt derav, og/eller en blodklumpingsinhibitor for prevensjon eller reduksjon av ugunstige bivirkninger hos en pasient. Typen pasient som kan trekke fordel av dette inkluderer en pasient med redusert venstreventrikulær funksjon, en pasient med et tidligere myokardialt infarkt, en pasient som undergår ikke-vaskulær kirurgi eller en fetus under veer og fødsel
NO20075400A 2005-03-28 2007-10-23 Anvendelse av AICA-ribosidanaloger NO342207B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66607105P 2005-03-28 2005-03-28
PCT/US2006/011422 WO2006105167A2 (en) 2005-03-28 2006-03-28 Methods, compositions, and formulations for preventing or reducing adverse effects in a patient

Publications (2)

Publication Number Publication Date
NO20075400L true NO20075400L (no) 2007-12-19
NO342207B1 NO342207B1 (no) 2018-04-16

Family

ID=37054068

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075400A NO342207B1 (no) 2005-03-28 2007-10-23 Anvendelse av AICA-ribosidanaloger

Country Status (14)

Country Link
US (3) US8993527B2 (no)
EP (3) EP3132796A1 (no)
JP (9) JP2008534601A (no)
KR (1) KR20070121026A (no)
CN (1) CN101184495B (no)
AU (1) AU2006230242B2 (no)
BR (1) BRPI0608654C1 (no)
CA (1) CA2602291C (no)
MX (1) MX2007012045A (no)
NO (1) NO342207B1 (no)
NZ (1) NZ561649A (no)
SG (3) SG10201704913RA (no)
WO (1) WO2006105167A2 (no)
ZA (1) ZA200708277B (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007012045A (es) 2005-03-28 2008-01-16 Pericor Therapeutics Inc Composiciones y formulaciones para evitar o reducir efectos adversos a un paciente.
US20070082859A1 (en) * 2005-10-07 2007-04-12 Stover Richard R Formulations of AICA riboside
WO2008086341A1 (en) * 2007-01-09 2008-07-17 Pericor Therapeutics, Inc. Methods. compositions, and formulations for preventing or reducing adverse effects in a patient
DE102008007216A1 (de) 2007-05-29 2008-12-11 Samsung Electro - Mechanics Co., Ltd., Suwon Gedruckte Leiterplatte und Herstellungsverfahren derselben
JP5591245B2 (ja) * 2008-10-03 2014-09-17 ペリコー セラピューティクス， インコーポレイテッド 急性心不全の治療のための方法および組成物
EP2512489A4 (en) * 2009-12-15 2014-04-02 Merck Sharp & Dohme FORMULATIONS FROM ACADESIN
US8489182B2 (en) 2011-10-18 2013-07-16 General Electric Company System and method of quality analysis in acquisition of ambulatory electrocardiography device data
US11160879B2 (en) 2014-01-15 2021-11-02 Masamichi Yamamoto Transgenic animal for visualization of ATP and use thereof
DK3107548T3 (da) 2014-02-20 2022-07-18 Otitopic Inc Tørpulverformuleringer til inhalation
CN104140438B (zh) * 2014-06-11 2017-01-18 苏州景泓生物技术有限公司 5‑氨基‑4‑氨甲酰咪唑核苷碳环类似物的合成方法
KR102666667B1 (ko) * 2014-07-31 2024-05-17 벡추라 인코포레이티드 흡입용 건조 분말 제형
WO2016176552A1 (en) 2015-04-30 2016-11-03 Otitopic Inc. Dry power formulations for inhalation
JP6937134B2 (ja) * 2016-11-21 2021-09-22 株式会社スタージェン 細胞内ａｔｐ増強剤
WO2018092911A1 (ja) * 2016-11-21 2018-05-24 株式会社スタージェン 細胞内ａｔｐ増強剤
WO2019039438A1 (ja) * 2017-08-21 2019-02-28 国立大学法人三重大学 非ヒト哺乳類の脳梗塞モデルによる観察方法及び非ヒト哺乳類の脳梗塞モデルによる観察装置
EP4040991A4 (en) * 2019-10-09 2024-01-24 Mayo Foundation for Medical Education and Research TREATMENT OF GASTROINTESTINAL DISORDERS
EP3866176A1 (en) * 2020-02-17 2021-08-18 Siemens Healthcare GmbH Machine-based risk prediction for peri-procedural myocardial infarction or complication from medical data
US12369883B2 (en) 2020-06-19 2025-07-29 Ultrasound AI, Inc. Artificial intelligence system for determining clinical values through medical imaging
US11266376B2 (en) 2020-06-19 2022-03-08 Ultrasound Ai Inc. Premature birth prediction
WO2024073384A2 (en) * 2022-09-26 2024-04-04 The Penn State Research Foundation Anticoagulant-peptide nanogranules for thrombosis-actuated anticoagulation
KR20250161553A (ko) * 2023-03-13 2025-11-17 울트라사운드 에이아이, 인코포레이티드 의료 이미징을 통한 포괄적인 의료 진단, 예후, 및 치료 최적화를 위한 인공 지능 시스템

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1645976A1 (de) 1966-06-18 1971-01-21 Ajinomoto Kk Verfahren zur Herstellung von Adenosin und 2',3'-O-Isopropylidenadenosin
JPS4944349B1 (no) * 1967-06-16 1974-11-27
US4211771A (en) * 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
AT350735B (de) 1976-08-06 1979-06-11 Hoffmann La Roche Verfahren zur herstellung von neuen ribo- furanosyl-imidazolderivaten
AU529815B2 (en) * 1981-05-15 1983-06-23 Fisons Plc Optically active imidazole derivatives
US4575498A (en) * 1983-07-21 1986-03-11 Duke University Method for restoring depleted purine nucleotide pools
US5030623A (en) * 1986-03-27 1991-07-09 The Regents Of The University Of California Methods for increasing extracellular adenosine and for stabilizing mast cells
US5008251A (en) * 1986-03-27 1991-04-16 The Regents Of The University Of California Method of treating autism
US5118601A (en) * 1986-03-27 1992-06-02 The Regents Of The University Of California Method of screening purine nucleoside compounds or analogs for the ability to enhance the cellular synthesis and release of adenosine
AU5668886A (en) 1986-03-27 1987-10-20 Harry Edward Gruber A method of increasing adenosine excretion
US4912092A (en) 1986-03-27 1990-03-27 The Regents Of The University Of California Methods for increasing extracellular adenosine and for stabilizing mast cells
US5658889A (en) * 1989-01-24 1997-08-19 Gensia Pharmaceuticals, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
US5132291A (en) * 1989-01-24 1992-07-21 Gensia Pharmaceuticals, Inc. Antivirals and methods for increasing the antiviral activity of azt
US5082829A (en) * 1989-01-24 1992-01-21 Gensia Pharmaceuticals AICA riboside prodrugs
US5200525A (en) * 1989-01-24 1993-04-06 Gensia Pharmaceuticals Anti-seizure compounds
FI921092A7 (fi) * 1989-09-15 1992-03-13 Gensia Pharma Menetelmä neurodegeneratiivisten tilojen hoitamiseksi
US5646128A (en) 1989-09-15 1997-07-08 Gensia, Inc. Methods for treating adenosine kinase related conditions
IL99125A0 (en) * 1990-08-10 1992-07-15 Gensia Pharma Derivatives of imidazole analog of aica riboside and their use
US5777100A (en) * 1990-08-10 1998-07-07 Gensia Inc. AICA riboside analogs
IL99124A (en) 1990-08-10 1998-02-22 Gensia Pharma Substituted imidazole analogs of aica riboside
IL103294A0 (en) 1991-09-30 1993-05-13 Gensia Pharma Pharmaceutical compositions for preventing tissue damage associated with decreased blood flow
CA2151588C (en) * 1992-12-16 2002-03-19 Michael D. Varney Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone
IL108524A0 (en) * 1993-02-03 1994-05-30 Gensia Inc Imidazodiazepine analogs
US5366960A (en) * 1993-08-26 1994-11-22 Warner-Lambert Company Method of treating cerebral and cardiovascular disorders employing [R]3-(2-deoxy-β-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidaz 0-[4,5-d][1,3]diazepin-8-ol
US5629298A (en) * 1995-03-13 1997-05-13 University Of Massachusetts Medical Center Adenosine as a positive inotrop in the compromised heart
US5645128A (en) * 1995-06-05 1997-07-08 Schwall; Charles F. Fire safety grease seal
US5998386A (en) * 1997-09-19 1999-12-07 Feldman; Arthur M. Pharmaceutical compositions and method of using same for the treatment of failing myocardial tissue
WO1999026657A1 (en) 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US20040072138A1 (en) 1997-11-25 2004-04-15 Medical University Of South Carolina Attenuation of ischemia/reperfusion injury
US6103702A (en) * 1999-05-24 2000-08-15 Board Of Trustees Of The University Of Illinois Use of adenosine deaminase inhibitors to treat systemic inflammatory response syndrome
EP1492564A2 (en) 2001-10-31 2005-01-05 Université Libre de Bruxelles Amp-kinase agonists or adenosine pro-drugs as immuno-stimulating agents
ES2192495B1 (es) * 2002-03-21 2005-02-16 Universidad De Barcelona Nuevo uso terapeutico del ribosido de 5-aminoimidazol-4-carboxamida (acadesina).
MX2007012045A (es) 2005-03-28 2008-01-16 Pericor Therapeutics Inc Composiciones y formulaciones para evitar o reducir efectos adversos a un paciente.
US20070082859A1 (en) 2005-10-07 2007-04-12 Stover Richard R Formulations of AICA riboside
WO2008086341A1 (en) 2007-01-09 2008-07-17 Pericor Therapeutics, Inc. Methods. compositions, and formulations for preventing or reducing adverse effects in a patient
WO2009094593A1 (en) 2008-01-25 2009-07-30 Foker John E Methods and compositions for inhibiting progression to chronic cardiac failure

Also Published As

Publication number Publication date
EP3132796A1 (en) 2017-02-22
BRPI0608654B8 (pt) 2020-10-27
JP2015057436A (ja) 2015-03-26
EP1863497A4 (en) 2009-08-12
JP2013010794A (ja) 2013-01-17
SG10201704913RA (en) 2017-07-28
NZ561649A (en) 2011-02-25
BRPI0608654A2 (pt) 2010-01-19
JP2017057222A (ja) 2017-03-23
BRPI0608654C1 (pt) 2021-05-25
CN101184495A (zh) 2008-05-21
AU2006230242B2 (en) 2013-05-30
JP2013010795A (ja) 2013-01-17
JP7093739B2 (ja) 2022-06-30
US20150272978A1 (en) 2015-10-01
JP2025084893A (ja) 2025-06-03
ZA200708277B (en) 2011-03-30
JP2008534601A (ja) 2008-08-28
KR20070121026A (ko) 2007-12-26
JP2020152737A (ja) 2020-09-24
WO2006105167A2 (en) 2006-10-05
WO2006105167A3 (en) 2007-05-10
JP6122417B2 (ja) 2017-04-26
EP1863497A2 (en) 2007-12-12
JP2019089853A (ja) 2019-06-13
CA2602291A1 (en) 2006-10-05
NO342207B1 (no) 2018-04-16
SG160425A1 (en) 2010-04-29
EP2594273A1 (en) 2013-05-22
JP2022093641A (ja) 2022-06-23
US20170216335A1 (en) 2017-08-03
CA2602291C (en) 2015-08-11
US20060293273A1 (en) 2006-12-28
AU2006230242A1 (en) 2006-10-05
BRPI0608654B1 (pt) 2020-09-29
US9539274B2 (en) 2017-01-10
CN101184495B (zh) 2011-09-14
SG194352A1 (en) 2013-11-29
US8993527B2 (en) 2015-03-31
MX2007012045A (es) 2008-01-16

Similar Documents

Publication Publication Date Title
NO20075400L (no) Fremgangsmater, sammensetninger og formuleringer for a forebygge eller lindre ugunstige virkninger i en pasient
IN2012DN04949A (no)
SA521422625B1 (ar) مركبات بنزوثيادايازيبين واستخدامها كمعدلات لحمض الصفراء
SG152262A1 (en) Improved modulators of coagulation factors
NO20090469L (no) Substituerte piperidiner som oker P53-aktiviteten, og anvendelse derav
EP3026044B8 (en) Prolyl hydroxylase inhibitors and methods of use
NO20072934L (no) Anvendelse av Ranolazon i kombinasjon med minst ett remodelleringsmiddel for a reversere remodellering av venstre ventikkel ved behandlingen av hjertesvikt
NO20070372L (no) Amidoforbindelser og anvendelse derav som farmasoytiske preparater
DK2324008T3 (da) Diarylpyrazol som protein kinase inhibitorer
WO2008011559A3 (en) Synthetic lung surfactant and use thereof
WO2005001079A3 (en) Soft tissue repair and regeneration using postpartum-derived cells
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
BRPI0510110A (pt) método para tratar, prevenir ou controlar hipertensão pulmonar, e, composição farmacêutica
WO2008017025A3 (en) Combination therapy
MX2014002471A (es) Combinaciones sinergicas de los inhibidores de p13k y mek.
WO2007146085A3 (en) Creatine phosphate prodrugs, compositions and uses thereof
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
BRPI0418742A (pt) métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de um sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit
EP4588487A3 (en) Treatment of warts
WO2006116185A3 (en) Methods for the treatment of multiple myeloma
WO2006029487A8 (en) Platelet factor 4 variant 1 (pf4var1) related inhibitors of angiogenesis
DE602005023437D1 (de) Als inhibitor von retroviraler protease geeignete ritonavir-analoge verbindung, herstellung der ritonavir-analogen verbindung und pharmazeutische zusammenetzung für die ritonavir-analoge verbindung
HK40080669A (en) Pharmaceutical composition for the treatment of pulmonary vascular disease and/or cardiac dysfunction in fontan-palliated patients
WO2005034844A3 (en) Exosite-directed thrombin inhibitors
Rothenberg et al. Correction to: Safety, Tolerability, and Pharmacokinetics of GDC‑0276, a Novel Na V 1.7 Inhibitor, in a First‑in‑Human, Single‑and Multiple‑Dose Study in Healthy Volunteers